
NERV
Healthcare · Biotechnology · $114.6M market cap
$2.32-0.06 (-2.5%)Nov 13, 4:00 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · 30-day revisions 1 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 6, 2026 | Before the open | -0.14 | -1.60 | -1042.9% |
| Aug 7, 2026 | Time not confirmed | -0.01 | -0.46 | -4500.0% |
| May 12, 2026 | Time not confirmed | -0.14 | -0.17 | -23.2% |
| Mar 11, 2026 | Before the open | -0.30 | -25.51 | -8403.3% |
| Nov 5, 2025 | Before the open | -0.35 | -0.36 | -2.9% |
| Aug 5, 2025 | Before the open | -0.90 | -0.43 | +52.2% |
| May 13, 2025 | Before the open | -1.07 | -0.50 | +53.3% |
| Feb 25, 2025 | Before the open | -1.05 | -0.56 | +46.7% |
| Nov 5, 2024 | Before the open | -1.01 | 2.97 | +394.1% |
| Aug 6, 2024 | Before the open | -0.97 | -1.09 | -12.4% |
| May 1, 2024 | Before the open | -1.20 | -1.13 | +5.8% |
| Feb 22, 2024 | Before the open | -0.88 | -1.39 | -58.0% |
| Nov 6, 2023 | After the close | -0.77 |
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based…
| -1.03 |
| -33.8% |
| Aug 1, 2023 | Before the open | -0.44 | -1.12 | -154.5% |
| May 15, 2023 | Before the open | -1.63 | -1.31 | +19.6% |
| Mar 8, 2023 | Before the open | -0.92 | -1.26 | -37.0% |
| Nov 9, 2022 | Before the open | -1.41 | -1.29 | +8.5% |
| Aug 9, 2022 | Before the open | -1.68 | -1.63 | +3.0% |
| May 4, 2022 | Before the open | -1.52 | -1.84 | -21.1% |
| Mar 1, 2022 | Before the open | -1.50 | -4.00 | -166.7% |
| Nov 8, 2021 | Before the open | -1.76 | -1.76 | 0.0% |
| Aug 2, 2021 | Before the open | -1.39 | -2.00 | -43.9% |
| May 12, 2021 | Before the open | 1.71 | -1.68 | -198.2% |
| Mar 8, 2021 | Before the open | -1.53 | -1.44 | +5.9% |
| Nov 2, 2020 | Before the open | -1.83 | -1.52 | +16.9% |
| Aug 3, 2020 | Before the open | -2.32 | 5.84 | +351.7% |
| May 4, 2020 | Before the open | -2.86 | -2.48 | +13.3% |
| Mar 9, 2020 | Before the open | -3.04 | -6.16 | -102.6% |
| Nov 4, 2019 | Before the open | -3.01 | -2.88 | +4.3% |
| Aug 5, 2019 | Before the open | -3.33 | -2.56 | +23.1% |
| May 6, 2019 | Before the open | -2.85 | -3.28 | -15.1% |
| Mar 12, 2019 | Before the open | -2.84 | -2.72 | +4.2% |
| Nov 5, 2018 | Before the open | -3.08 | -2.48 | +19.5% |
| Aug 2, 2018 | Before the open | -3.15 | -2.56 | +18.7% |
| May 3, 2018 | Before the open | -2.07 | -2.56 | -23.7% |
| Mar 12, 2018 | Before the open | -3.04 | -1.92 | +36.8% |